MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $2.29 Million Stake in 10x Genomics, Inc. (NASDAQ:TXG)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 37.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 159,165 shares of the company's stock after purchasing an additional 42,950 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned about 0.13% of 10x Genomics worth $2,286,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Atria Wealth Solutions Inc. increased its holdings in 10x Genomics by 9.6% in the 4th quarter. Atria Wealth Solutions Inc. now owns 10,788 shares of the company's stock worth $155,000 after purchasing an additional 943 shares in the last quarter. Blue Trust Inc. grew its holdings in shares of 10x Genomics by 73.1% during the fourth quarter. Blue Trust Inc. now owns 3,075 shares of the company's stock worth $44,000 after purchasing an additional 1,299 shares during the last quarter. Sound Income Strategies LLC increased its stake in shares of 10x Genomics by 65.2% in the fourth quarter. Sound Income Strategies LLC now owns 3,370 shares of the company's stock valued at $48,000 after buying an additional 1,330 shares during the period. Signaturefd LLC raised its holdings in 10x Genomics by 424.6% in the 4th quarter. Signaturefd LLC now owns 1,794 shares of the company's stock valued at $26,000 after buying an additional 1,452 shares during the last quarter. Finally, KBC Group NV raised its holdings in 10x Genomics by 57.3% in the 4th quarter. KBC Group NV now owns 5,072 shares of the company's stock valued at $73,000 after buying an additional 1,847 shares during the last quarter. 84.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at 10x Genomics

In other 10x Genomics news, insider Benjamin J. Hindson sold 4,573 shares of the firm's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $11.07, for a total value of $50,623.11. Following the transaction, the insider now directly owns 335,324 shares of the company's stock, valued at approximately $3,712,036.68. This trade represents a 1.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Alan Mateo acquired 40,000 shares of 10x Genomics stock in a transaction dated Friday, February 21st. The shares were acquired at an average price of $11.14 per share, with a total value of $445,600.00. Following the completion of the acquisition, the director now directly owns 61,691 shares of the company's stock, valued at approximately $687,237.74. The trade was a 184.41% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 9.39% of the company's stock.

10x Genomics Stock Down 8.4%

Shares of NASDAQ TXG opened at $8.32 on Thursday. The firm has a market cap of $1.02 billion, a PE ratio of -5.47 and a beta of 1.94. The company's fifty day simple moving average is $8.68 and its 200 day simple moving average is $12.21. 10x Genomics, Inc. has a 12-month low of $6.78 and a 12-month high of $24.76.

10x Genomics (NASDAQ:TXG - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.45) by $0.09. The company had revenue of $154.88 million for the quarter, compared to analysts' expectations of $131.91 million. 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. The business's revenue was down 2.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.50) EPS. On average, equities analysts predict that 10x Genomics, Inc. will post -1.43 earnings per share for the current year.

Wall Street Analysts Forecast Growth

TXG has been the subject of several analyst reports. Stifel Nicolaus lowered their target price on 10x Genomics from $21.00 to $18.00 and set a "buy" rating for the company in a research report on Thursday, February 13th. Leerink Partnrs cut 10x Genomics from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 13th. Morgan Stanley cut their price objective on 10x Genomics from $26.00 to $18.00 and set an "overweight" rating on the stock in a research note on Monday. JPMorgan Chase & Co. decreased their target price on shares of 10x Genomics from $12.00 to $9.00 and set a "neutral" rating for the company in a research report on Friday, May 9th. Finally, Canaccord Genuity Group lowered their price target on shares of 10x Genomics from $18.00 to $15.00 and set a "buy" rating for the company in a report on Monday, May 12th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $15.81.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.